Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.

Abstract: A method, system and tool are disclosed for estimating headcounts. An input and selected metric are received. The metric is selected based on a span of control. A full-time equivalent is calculated in accordance with the input and the selected metric.

Abstract: Hydrocarbon and carbon monoxide emission of an internal combustion engine fitted with a non-catalytic thermal exhaust reactor is substantially lowered by operating the engine lean during normal modes of engine operation and switching to rich operation during idle using restricted air injection such that the idle exhaust contains about 2-5 volume percent oxygen.